Filtered By:
Procedure: Laparoscopy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

The use of sealing hemostat patch (HEMOPATCH ®) in laparotomic myomectomy: a prospective case–control study
ConclusionsHEMOPATCH®, during laparotomic myomectomy, is a valid alternative solution for obtaining rapid hemostasis and consequently intraoperative and postoperative bleeding. Furthermore, we suggest that a lower inflammatory peritoneal state is probably correlated with the barrier effect of the patch on the suture.
Source: Archives of Gynecology and Obstetrics - February 15, 2023 Category: OBGYN Source Type: research

Ruptured Corpus Luteum with Hemoperitoneum in Early Pregnancy
We present a 24-year-old woman with a positive ß HCG at 5 weeks and 4 days with acute post-coital lower abdominal pain. Imaging revealed acute intra - abdominal bleeding and no intra-or extra uterine fetal sac present, We considered both ruptured ectopic pregnancy and ovarian hemorrhage – recognising that differentiation is difficult. At emer gency laparoscopy (Figure 1), the enlarged left ovary was actively bleeding, and luteal rupture with hemorrhage was diagnosed. Intraperitoneal lavage was performed, and hemostasis was achieved using bipolar coagulation and hemostatic agents (SURGICEL® Powder Absorbable Hemostat; E...
Source: The Journal of Minimally Invasive Gynecology - November 12, 2022 Category: OBGYN Authors: Masafumi Katakura, Yu Suzuki, Tadashi Namihira, Masahiro Ezawa, Takamasa Furukawa, Masahito Nakakuma Tags: Images in Gynecologic Surgery Source Type: research

Use of hemostatic agents for surgical bleeding in laparoscopic partial nephrectomy: Biomaterials perspective
AbstractIn recent years, there was an abrupt increase in the incidence of renal tumors, which prompt up the appearance of cutting ‐edge technology, including minimally invasive and organ‐preserving approaches, such as laparoscopic partial nephrectomy (LPN). LPN is an innovative technique used to treat small renal masses that have been gaining popularity in the last few decades due to its promissory results. However, the bl eeding control remains the main challenge since the majority of currently available hemostatic agents (HAs) used in other surgical specialities are inefficient in LPN. This hurried the search for eff...
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - May 25, 2020 Category: Materials Science Authors: Margarida Pacheco, Alexandre A. Barros, Ivo M. Aroso, Riccardo Autorino, Est êvão Lima, Joana M. Silva, Rui L. Reis Tags: REVIEW ARTICLE Source Type: research

Use of hemostatic agents for surgical bleeding in laparoscopic partial nephrectomy: Biomaterials perspective.
Abstract In recent years, there was an abrupt increase in the incidence of renal tumors, which prompt up the appearance of cutting-edge technology, including minimally invasive and organ-preserving approaches, such as laparoscopic partial nephrectomy (LPN). LPN is an innovative technique used to treat small renal masses that have been gaining popularity in the last few decades due to its promissory results. However, the bleeding control remains the main challenge since the majority of currently available hemostatic agents (HAs) used in other surgical specialities are inefficient in LPN. This hurried the search for...
Source: Biomed Res - May 25, 2020 Category: Research Authors: Pacheco M, Barros AA, Aroso IM, Autorino R, Lima E, Silva JM, Reis RL Tags: J Biomed Mater Res B Appl Biomater Source Type: research

Evaluation of a Chitosan Hemostat in a Porcine Laparoscopic Partial Nephrectomy Model: A Pilot Study
Journal of Endourology,Volume 33, Issue 11, Page 887-894, November 2019.
Source: Journal of Endourology - November 7, 2019 Category: Urology & Nephrology Authors: Andrew Crofton Duane Baldwin Muhannad Alsyouf Matthew Dopp Daniel Faaborg Kristine Myklak Javier Arenas Nazih Khater Samuel Hudson Kerby C. Oberg Wolff M. Kirsch Source Type: research

Editorial Comment on: Evaluation of a Chitosan Hemostat in a Porcine Laparoscopic Partial Nephrectomy Model: A Pilot Study by Crofton et al. (From: Crofton A, Baldwin D, Alsyouf M, et al. J Endourol 2019 Epub ahead of print; DOI: 10.1089/end.2018.0801)
Journal of Endourology, Ahead of Print.
Source: Journal of Endourology - August 21, 2019 Category: Urology & Nephrology Authors: David S. Wang Source Type: research

Comparison between LigaSure ™ and Harmonic® in Laparoscopic Sleeve Gastrectomy: A Single-Center Experience on 422 Patients.
Conclusion: Harmonic® and LigaSure™ are both useful tools in bariatric surgery, and these two advanced power devices are user-friendly and can facilitate surgeon work; from this point of view, the choice of the energy device should be based on the preference of the surgeon and on the hospital costs policy and availability. PMID: 30719344 [PubMed - in process]
Source: Journal of Obesity - February 7, 2019 Category: Eating Disorders & Weight Management Tags: J Obes Source Type: research

Advanced Medical Solutions Group plc: Acquisition of Sealantis
Winsford, UK, 31 January 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces it has acquired Sealantis Limited ( “Sealantis”), a developer of an alginate-based tissue adhesive technology platform, for $US 25m (approximately £19m) in cash with royalties due until December 2027 on sales of any of its products that are currently in development.Overview of SealantisSealantis is an Israeli-based medical device company with a patent-protected alga-mimetic sealants technology platform with a wide range of potential surgical indications under developm...
Source: Medical Hemostat - February 1, 2019 Category: Medical Devices Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

J & J ’ s Ethicon launches ProxiSure laparoscopic suturing device
Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon said today it launched the ProxiSure laparoscopic suturing device. Ethicon said the device features its endomechanical, suture and curved needle technologies to improve suturing precision in tight spaces. The device allows surgeons to reach desired angles, control bites and secure nots during suturing and knot tying to reduce the risk of needle loss, the company added. “With the patient’s health at the forefront of our thinking, we aimed to introduce a suturing device that will help reduce the margin of error in minimally-invasive surgery. Surgeons will now b...
Source: Mass Device - August 21, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blog Ethicon johnsonandjohnson Source Type: news

A novel procedure for introducing large sheet-type surgical material with a self-expanding origami structure using a slim trocar (chevron pleats procedure)
ConclusionsCPP is a basic utility procedure for introducing several sheet-type surgical materials into a corporeal cavity with a 5-mm trocar and might help ensure efficient and safe laparoscopic surgery.
Source: Surgical Endoscopy - December 29, 2016 Category: Surgery Source Type: research

Fibrin Glue Market: Asia is expected to witness high growth rates in the next five years, 2021
Fibrin glue is a unique adhesion material used in surgeries for closure of wounds. Fibrin glues are mainly extracted from collective plasma and contain different amounts of purified and virally-inactivated human proteins. Fibrin glue is composed of two components, including fibrinogen and factor XIII. These concentrated ingredients interact with a solution of thrombin and calcium to form coagulum. As the thrombin and fibrinogen/factor XIII solution combine, a clot of a blood protein called fibrin develops in a few seconds, depending on the dilute form of thrombin is used. Some of the characteristics of fibrin glue include ...
Source: Medical Hemostat - November 19, 2016 Category: Medical Equipment Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Arch Therapeutics raises $3.4m to support novel blood control dev
Arch Therapeutics (OTC:ARTH) said last week it raised $3.4 million through the private placement of the company’s securities with a group of investors. The Framingham, Mass.-based company said it floated approximately 9.5 million shares at 36¢ per share in the placement round. Each unit offered in the round includes 1 share of common stock and 1 Series E warrant to purchase 3/4 of a share of common stock at 44¢ per share for up to 5 years. The company said it expects to offer approximately 7.1 million Series E warrants along with the 9.5 million shares, according to a press release. Maxim Group acted as the placeme...
Source: Mass Device - May 31, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Business/Financial News Arch Therapeutics Source Type: news

Arch Therapeutics launches EU trial for AC5 hemostat
Arch Therapeutics (OTC:ARTH) said today that it launched a European safety-and-efficacy study of its AC5 surgical hemostat in bleeding wounds incurred during dermatology procedures. Framingham, Mass.-based Arch, which won approval for the randomized, controlled, single-blind study last December, said the 46-patient trial will include a 10-subject arm who are taking blood thinners. Each patient will have at least 2 lesions removed, with 1 wound treated using the AC5 hemostat and the 2nd with a control treatment. Arch bills AC5 as designed to stop bleeding in seconds, rather than minutes, and conform to wound geometries wh...
Source: Mass Device - March 7, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Surgical Arch Therapeutics Source Type: news

28: Factors associated with hemostat use during laparoscopic hysterectomy
To determine factors associated with use of hemostats at the time of hysterectomy.
Source: American Journal of Obstetrics and Gynecology - March 6, 2016 Category: OBGYN Authors: A.B. Kakos, V. Allen, J. Whiteside Tags: Non-Oral Poster Source Type: research